Objective  To evaluate the role of novel nanomaterial MN receptor targeted inhibition system (MTIS) in targeting and inhibiting clear cell renal cell carcinoma (ccRCC).

Methods  The microprobe MTIS was designed and implemented for use with ccRCC cell lines 786- O and Caki-1. The targeting efficacy of both MTIS and MN was examined through laser scanning confocal microscopy (CLSM). CCK-8 and Transwell assays were conducted to confirm the inhibitory impact of MTIS on ccRCC. Additionally, the Renca cell line was utilized to induce subcutaneous tumors in mice, and MTIS was administered through tail vein injection to assess its therapeutic effect.

Results  The CLSM observations revealed that MTIS exhibited excellent colocalization with tumor cells. The results from CCK-8 and Transwell experiments further demonstrated that MTIS significantly inhibited the migration and invasion of tumor cells. Furthermore, the effective concentration of MTIS injected via tail vein at the tumor site in mice was observed using the in vivo imaging system (IVIS). Notably, the tumor volume in mice after 14, 21 and 28 days treated with MTIS were markedly smaller compared to the control group (P<0.05).

Conclusion  The novel nanoprobe MTIS effectively targets ccRCC cells and demonstrates a significant inhibitory effect on their migration and invasion.

1.Usher-Smith J, Simmons RK, Rossi SH, et al. Current evidence on screening for renal cancer[J]. Nat Rev Urol, 2020, 17(11): 637-642. DOI: 10.1038/s41585-020-0363-3.

2.Rose TL, Kim WY. Renal cell carcinoma: a review[J]. JAMA, 2024, 332(12): 1001-1010. DOI: 10.1001/jama.2024.12848.

3.Lyskjær I, Iisager L, Axelsen CT, et al. Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic[J]. Clin Cancer Res, 2024, 30(4): 663-672. DOI: 10.1158/1078-0432.CCR-23-1892.

4.Mo DC, Huang JF, Luo PH, et al. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: a Meta-analysis of randomized controlled trials[J]. Clin Immunol, 2021, 232: 108876. DOI: 10.1016/j.clim.2021.108876.

5.Keum H, Cevik E, Kim J, et al. Tissue ablation: applications and perspectives[J]. Adv Mater, 2024, 36(32): e2310856. DOI: 10.1002/adma.202310856.

6.Zhou X, Liu Q, Yuan W, et al. Ultrabright NIR-II emissive polymer dots for metastatic ovarian cancer detection[J]. Adv Sci (Weinh), 2021, 8(4): 2000441. DOI: 10.1002/advs.202000441.

7.Hernot S, van Manen L, Debie P, et al. Latest developments in molecular tracers for fluorescence image-guided cancer surgery[J]. Lancet Oncol, 2019, 20(7): e354-e367. DOI: 10.1016/S1470-2045(19)30317-1.

8.Raina P, Singh SK, Goswami AK, et al. MN/CA9 gene expression as a potential tumor marker for renal cell carcinoma[J]. Mol Cell Biochem, 2022, 477(2): 333-343. DOI: 10.1007/s11010-021-04279-y.

9.Zakšauskas A, Čapkauskaitė E, Paketurytė-Latvė V, et al. Methyl 2-Halo-4-Substituted-5-Sulfamoyl-Benzoates as high affinity and selective inhibitors of carbonic anhydrase IX[J]. Int J Mol Sci, 2021, 23(1): 130. DOI: 10.3390/ijms23010130.

10.Iagaru A , Takalkar A , Higgins G, et al. 89 Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX[J]. J Clin Oncol, 2023, 41(6_suppl): tps738. DOI: 10.1200/jco.2023.41.6_suppl.tps738.

11.Horikawa M, Sabe H, Onodera Y. Dual roles of AMAP1 in the transcriptional regulation and intracellular trafficking of carbonic anhydrase IX[J]. Transl Oncol, 2022, 15(1): 101258. DOI: 10.1016/j.tranon.2021.101258.

12.Courcier J, de la Taille A, Nourieh M, et al. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management[J]. Int J Mol Sci, 2020, 21(19): 7146. DOI: 10.3390/ijms21197146.

13.Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708.

14.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.

15.Mao X, Wang G, Wang Z, et al. Theranostic lipid nanoparticles for renal cell carcinoma[J]. Adv Mater, 2023, 25: e2306246. DOI: 10.1002/adma.202306246.

16.Li QK, Pavlovich CP, Zhang H, et al. Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): a critical step towards the personalized care of renal cancers[J]. Semin Cancer Biol, 2019, 55: 8-15. DOI: 10.1016/j.semcancer.2018.06.004.

17.Li M, Li L, Zheng J, et al. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application[J]. Mol Cancer, 2023, 22(1): 37. DOI: 10.1186/s12943-023-01745-7.

18.Wu R, Wang K, Gai Y, et al. Nanomedicine for renal cell carcinoma: imaging, treatment and beyond[J]. J Nanobiotechnology, 2023, 21(1): 3. DOI: 10.1186/s12951-022-01761-7.

19.Queen A, Bhutto HN, Yousuf M, et al. Carbonic anhydrase IX: a tumor acidification switch in heterogeneity and chemokine regulation[J]. Semin Cancer Biol, 2022, 86(Pt 3): 899-913. DOI: 10.1016/j.semcancer.2022.01.001.

20.Hsin MC, Hsieh YH, Hsiao YH, et al. Carbonic anhydrase IX promotes human cervical cancer cell motility by regulating PFKFB4 expression[J]. Cancers (Basel), 2021, 13(5): 1174. DOI: 10.3390/cancers13051174.

21.Daunys S, Petrikaitė V. The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis[J]. Biol Cell, 2020, 112(12): 383-397. DOI: 10.1111/boc.201900099.

22.Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond[J]. Cancer Metastasis Rev, 2019, 38(1-2): 65-77. DOI: 10.1007/s10555-019-09799-0.

23.Son J, Yi G, Yoo J, et al. Light-responsive nanomedicine for biophotonic imaging and targeted therapy[J]. Adv Drug Deliv Rev, 2018, 138: 133-147. DOI: 10.1016/j.addr.2018.10.002.